Gerardo Aguilar1, José Ramón Azanza2, José A Carbonell3, Carlos Ferrando3, Rafael Badenes3, María Asunción Parra2, Belén Sadaba2, David Navarro4, Jaume Puig3, Amanda Miñana3, Carlos Garcia-Marquez3, Gergana Gencheva3, Andrea Gutierrez3, Francisco J Marti3, F Javier Belda5. 1. Surgical Intensive Care Unit, Department of Anesthesiology and Intensive Care, Hospital Clínico Universitario de Valencia, Valencia, Spain gerardo.aguilar@uv.es. 2. Department of Clinical Pharmacology, University of Navarra Clinic, Pamplona, Spain. 3. Surgical Intensive Care Unit, Department of Anesthesiology and Intensive Care, Hospital Clínico Universitario de Valencia, Valencia, Spain. 4. Department of Microbiology, Hospital Clínico Universitario de Valencia, Valencia, Spain School of Medicine, University of Valencia, Valencia, Spain. 5. Surgical Intensive Care Unit, Department of Anesthesiology and Intensive Care, Hospital Clínico Universitario de Valencia, Valencia, Spain School of Medicine, University of Valencia, Valencia, Spain.
Abstract
BACKGROUND: Anidulafungin is indicated as a first-line treatment for invasive candidiasis in critically ill patients. In the intensive care unit, sepsis is the main cause of acute renal failure, and treatment with continuous renal replacement therapy (CRRT) has increased in recent years. Antimicrobial pharmacokinetics is affected by CRRT, but few studies have addressed the optimal dosage for anidulafungin during CRRT. PATIENTS AND METHODS: We included 12 critically ill patients who received continuous venovenous haemodiafiltration to treat acute renal failure. Anidulafungin was infused on 3 consecutive days, starting with a loading dose (200 mg) on Day 1, and doses of 100 mg on Days 2 and 3. Blood and ultradiafiltrate samples were collected on Day 3 (during steady-state) before, and at regular intervals after, the infusion had started. Anidulafungin concentrations were determined with HPLC. RESULTS: On Day 3, peak plasma concentrations with the 100 mg dose were 6.2 ± 1.7 mg/L and 7.1 ± 1.9 mg/L in the arterial and venous samples, respectively. The mean, pre-filter trough concentration was 3.0 ± 0.6 mg/L. The mean AUC0-24 values for plasma anidulafungin were 93.9 ± 19.4 and 104.1 ± 20.3mg·h/L in the arterial and venous samples, respectively. There was no adsorption to synthetic surfaces, and the anidulafungin concentration in the ultradiafiltrate was below the limit of detection. CONCLUSION: The influence of CRRT on anidulafungin elimination appeared to be negligible. Therefore, we recommend no adjustments to the anidulafungin dose for patients receiving CRRT.
BACKGROUND:Anidulafungin is indicated as a first-line treatment for invasive candidiasis in critically illpatients. In the intensive care unit, sepsis is the main cause of acute renal failure, and treatment with continuous renal replacement therapy (CRRT) has increased in recent years. Antimicrobial pharmacokinetics is affected by CRRT, but few studies have addressed the optimal dosage for anidulafungin during CRRT. PATIENTS AND METHODS: We included 12 critically illpatients who received continuous venovenous haemodiafiltration to treat acute renal failure. Anidulafungin was infused on 3 consecutive days, starting with a loading dose (200 mg) on Day 1, and doses of 100 mg on Days 2 and 3. Blood and ultradiafiltrate samples were collected on Day 3 (during steady-state) before, and at regular intervals after, the infusion had started. Anidulafungin concentrations were determined with HPLC. RESULTS: On Day 3, peak plasma concentrations with the 100 mg dose were 6.2 ± 1.7 mg/L and 7.1 ± 1.9 mg/L in the arterial and venous samples, respectively. The mean, pre-filter trough concentration was 3.0 ± 0.6 mg/L. The mean AUC0-24 values for plasma anidulafungin were 93.9 ± 19.4 and 104.1 ± 20.3mg·h/L in the arterial and venous samples, respectively. There was no adsorption to synthetic surfaces, and the anidulafungin concentration in the ultradiafiltrate was below the limit of detection. CONCLUSION: The influence of CRRT on anidulafungin elimination appeared to be negligible. Therefore, we recommend no adjustments to the anidulafungin dose for patients receiving CRRT.
Authors: M G Vossen; D Knafl; M Haidinger; R Lemmerer; M Unger; S Pferschy; W Lamm; A Maier-Salamon; W Jäger; F Thalhammer Journal: Antimicrob Agents Chemother Date: 2017-07-25 Impact factor: 5.191
Authors: Daniela Baracaldo-Santamaría; Juan David Cala-Garcia; Germán José Medina-Rincón; Luis Carlos Rojas-Rodriguez; Carlos-Alberto Calderon-Ospina Journal: Antibiotics (Basel) Date: 2022-05-12
Authors: Siang Fei Yeoh; Tae Jin Lee; Ka Lip Chew; Stephen Lin; Dennis Yeo; Sajita Setia Journal: Infect Drug Resist Date: 2018-05-30 Impact factor: 4.003